| Dr Brad H Lilly, DPM | |
|
3131 College Heights Blvd, Suite 1500, Allentown, PA 18104-4812 | |
| (610) 821-0444 | |
| (610) 820-7006 |
| Full Name | Dr Brad H Lilly |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 28 Years |
| Location | 3131 College Heights Blvd, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427165422 | NPI | - | NPPES |
| 013746 | Other | PA | HIGHMARK BLUE SHIELD |
| 0659158000 | Other | INDEPENCE BLUE CROSS | |
| 50003290 | Other | CAPITAL BLUE CROSS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | SC004243L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lehigh Valley Hospital | Allentown, PA | Hospital |
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| Provider Name | Defeo And Lilly Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1518069749 PECOS PAC ID: 9436134020 Enrollment ID: O20040618001092 |
News Archive
UC San Francisco researchers have discovered how a mutation in a gene regulator called the TERT promoter - the third most common mutation among all human cancers and the most common mutation in the deadly brain cancer glioblastoma - confers "immortality" on tumor cells, enabling the unchecked cell division that powers their aggressive growth.
Trius Therapeutics, Inc. announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI).
Commonly used ICU risk scores can be "repurposed" as continuous markers of severity of illness in critically ill patients-providing ongoing updates on changes in the patient's condition and risk of death, according to a study in the March issue of Critical Care Medicine, official journal of the Society of Critical Care Medicine. The journal is published by Wolters Kluwer.
Taking the recession's impact and reform together, the Obama years' Medicaid expansion (assuming the president and reform survive) will come to about 26 percent, higher than the Clinton years, no doubt, but significantly smaller than the increases experienced under either of the Bushes.
Switching to tenofovir may stave further kidney and bone impairment in patients with hepatitis B virus-related chronic hepatitis taking adefovir-based therapy, retrospective study findings suggest.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brad H Lilly, DPM 3131 College Heights Blvd, Suite 1500, Allentown, PA 18104-4812 Ph: (610) 821-0444 | Dr Brad H Lilly, DPM 3131 College Heights Blvd, Suite 1500, Allentown, PA 18104-4812 Ph: (610) 821-0444 |
News Archive
UC San Francisco researchers have discovered how a mutation in a gene regulator called the TERT promoter - the third most common mutation among all human cancers and the most common mutation in the deadly brain cancer glioblastoma - confers "immortality" on tumor cells, enabling the unchecked cell division that powers their aggressive growth.
Trius Therapeutics, Inc. announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI).
Commonly used ICU risk scores can be "repurposed" as continuous markers of severity of illness in critically ill patients-providing ongoing updates on changes in the patient's condition and risk of death, according to a study in the March issue of Critical Care Medicine, official journal of the Society of Critical Care Medicine. The journal is published by Wolters Kluwer.
Taking the recession's impact and reform together, the Obama years' Medicaid expansion (assuming the president and reform survive) will come to about 26 percent, higher than the Clinton years, no doubt, but significantly smaller than the increases experienced under either of the Bushes.
Switching to tenofovir may stave further kidney and bone impairment in patients with hepatitis B virus-related chronic hepatitis taking adefovir-based therapy, retrospective study findings suggest.
› Verified 3 days ago
Daniel Charles Fritz, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2414 Walbert Ave, Allentown, PA 18104 Phone: 610-434-7000 | |
Dr. Adam Jay Teichman, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2895 Hamilton Blvd Ste 101, Allentown, PA 18104 Phone: 610-330-9740 Fax: 610-432-4887 | |
Dr. Kevin Short, D.P.M Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2414 Walbert Ave, Allentown, PA 18104 Phone: 610-434-7000 Fax: 610-434-7029 | |
Dr. Melody Sue Stouder, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1736 Hamilton St, Allentown, PA 18104 Phone: 610-628-8364 | |
David P Steed, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 401 N 17th St, Ste 107, Allentown, PA 18104 Phone: 610-770-0110 | |
Douglas Tozzoli, Dpm Pc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 501 N 17th St, Suite 107, Allentown, PA 18104 Phone: 610-432-9593 | |
Scott Lipkin, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 401 N 17th St, Ste 107, Allentown, PA 18104 Phone: 610-770-0110 |